Biohaven Shares Fluctuate Following Positive Study Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BHVN?
Source: Benzinga
- Positive Clinical Data: Xenon Pharmaceuticals' X-TOLE2 study demonstrated a median percentage change of -42.7% in monthly focal onset seizure frequency for azetukalner at the 25 mg dose, providing short-term support for Biohaven's stock, despite its own BHV-7000 failing to meet primary endpoints in a Phase 2 trial for depression.
- Stock Performance Analysis: Biohaven shares peaked at $12.52 during premarket trading on Monday but fell back to $9.93, which is 12.5% below its 20-day simple moving average, indicating a bearish trend in the short term, with a 64.95% decline over the past year.
- Technical Indicator Insights: The current Relative Strength Index (RSI) stands at 36.10, indicating neutral territory, while the MACD value of -0.3294 is below its signal line of -0.1633, suggesting bearish pressure on the stock, with key resistance at $10.50 and support at $9.50.
- Analyst Ratings and Targets: While Biohaven's stock carries a Buy rating with an average price target of $30.36, recent actions show HC Wainwright & Co. lowering its target to $10.00, while RBC Capital raised its target to $23.00, reflecting differing analyst perspectives on the stock's outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 10.210
Low
11.00
Averages
18.00
High
30.00
Current: 10.210
Low
11.00
Averages
18.00
High
30.00
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Xenon Plans New Drug Application Submission
- Trial Results Exceed Expectations: Xenon announced that its azetukalner showed a median percent change of 53.2% in monthly focal onset seizure frequency at the 25 mg dose, significantly outperforming the placebo's 10.4%, which not only validates the drug's efficacy but also lays a solid foundation for future FDA submissions.
- New Drug Application Plans: The company plans to submit a new drug application for azetukalner to the U.S. FDA in Q3 2026, with CEO Ian Mortimer stating that the trial results “exceeded expectations,” potentially reshaping the epilepsy treatment landscape to meet the needs of 50% of patients seeking better control.
- Positive Market Reaction: Following the trial data announcement, Xenon's stock surged 50%, with Jefferies and RBC Capital raising their price targets to $100 and $80 respectively, reflecting strong market confidence in azetukalner and its significant sales potential in the future.
- Competitor Dynamics: Despite Biohaven's opakalim having safety disadvantages, Raymond James maintains a ‘Strong Buy’ rating, anticipating pivotal trial results in H2 2026 that will further clarify its market positioning.
See More
Biohaven Shares Fluctuate Following Positive Study Data
- Positive Clinical Data: Xenon Pharmaceuticals' X-TOLE2 study demonstrated a median percentage change of -42.7% in monthly focal onset seizure frequency for azetukalner at the 25 mg dose, providing short-term support for Biohaven's stock, despite its own BHV-7000 failing to meet primary endpoints in a Phase 2 trial for depression.
- Stock Performance Analysis: Biohaven shares peaked at $12.52 during premarket trading on Monday but fell back to $9.93, which is 12.5% below its 20-day simple moving average, indicating a bearish trend in the short term, with a 64.95% decline over the past year.
- Technical Indicator Insights: The current Relative Strength Index (RSI) stands at 36.10, indicating neutral territory, while the MACD value of -0.3294 is below its signal line of -0.1633, suggesting bearish pressure on the stock, with key resistance at $10.50 and support at $9.50.
- Analyst Ratings and Targets: While Biohaven's stock carries a Buy rating with an average price target of $30.36, recent actions show HC Wainwright & Co. lowering its target to $10.00, while RBC Capital raised its target to $23.00, reflecting differing analyst perspectives on the stock's outlook.
See More
Biohaven Reports Q4 Non-GAAP EPS Beat Expectations
- Earnings Performance: Biohaven reported a Q4 non-GAAP EPS of -$0.90, beating market expectations by $0.06, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Cash Reserves: As of December 31, 2025, Biohaven's cash, cash equivalents, marketable securities, and restricted cash totaled approximately $322 million, providing ample funding for future R&D and operations, thereby reducing the risk of a cash flow crisis in the short term.
- Stock Issuance Plan: Biohaven plans to sell 12.5 million shares to Janus Henderson for gross proceeds of $125 million, which will help strengthen the company's capital structure but may also lead to dilution risks for shareholders, necessitating careful assessment of its long-term impact.
- Market Reaction: Biohaven's presentation at the J.P. Morgan Healthcare Conference garnered investor interest, and despite challenges related to cash flow and dilution risks, the market maintains a cautiously optimistic outlook on its future growth opportunities, reflecting investor expectations for potential upside.
See More
Wall Street Analysts Upgrade Ratings and Price Targets for Multiple Companies
- Watts Water Upgrade: Keybanc analyst Jeffrey Hammond upgraded Watts Water Technologies Inc (NYSE:WTS) from Sector Weight to Overweight with a price target of $340, reflecting confidence in its growth potential, closing at $289.31 on Tuesday.
- Biohaven Price Target Raised: RBC Capital analyst Leonid Timashev upgraded Biohaven Ltd (NYSE:BHVN) from Sector Perform to Outperform, raising the price target from $9 to $22, indicating optimism about its product prospects, with shares closing at $12.68 on Tuesday.
- Ulta Beauty Rating Upgrade: Raymond James analyst Olivia Tong upgraded Ulta Beauty Inc (NASDAQ:ULTA) from Outperform to Strong Buy, increasing the price target from $605 to $790, showcasing strong confidence in its market performance, with shares closing at $675.62 on Tuesday.
- Albemarle Price Target Increase: Truist Securities analyst Peter Osterland upgraded Albemarle Corp (NYSE:ALB) from Hold to Buy, boosting the price target from $125 to $205, signaling positive expectations for its future performance, with shares closing at $172.54 on Tuesday.
See More
RBC Upgrades Biohaven to Outperform on Positive Drug Data, $22 Price Target Implies 74% Upside
- Rating Upgrade: RBC Capital Markets upgraded Biohaven from sector perform to outperform, with analyst Timashev noting that new data has reduced uncertainty around the company's epilepsy drug, setting a price target of $22, implying a 74% upside.
- Data Support: Recent January data indicates that Biohaven's Kv7 drug shows activity in the central nervous system, alleviating investors' worst-case concerns ahead of upcoming late-stage trials, thus boosting market confidence.
- Market Potential: Timashev believes the Kv7 modulator may demonstrate a better safety profile than competitors and has the potential to be a fast follower in a market that can support multiple branded drugs, enhancing Biohaven's competitive edge.
- Financial Outlook: While Biohaven still carries a relatively high risk profile, the analyst highlights that the improved financial position and discount relative to the platform's opportunity create an attractive setup for catalysts in 2H26, with successful clinical trials potentially pushing the stock price to $30, indicating nearly 137% upside.
See More
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data
- Stock Surge: Biohaven's shares rose 3.42% to $12.10 in after-hours trading on Wednesday, reflecting positive market sentiment towards its clinical data despite a 67.11% decline over the past year.
- SEC Filing Disclosure: The company filed an investor presentation with the SEC on Monday, showcasing portfolio progress at the 44th Annual J.P. Morgan Healthcare Conference, indicating compliance with transparency and fair disclosure regulations.
- Clinical Data Highlights: BHV-1400 achieved over 60% mean Gd-IgA1 reductions in Phase 1 studies for IgA nephropathy, with two patients showing clinical improvements, underscoring the drug's potential in treating immunological diseases.
- Future Catalysts: Biohaven anticipates pivotal trial results in 2026 for multiple drugs, including those targeting obesity and Graves' disease, demonstrating the company's ongoing commitment to R&D and future growth potential.
See More
Xenon Plans New Drug Application Submission
- Trial Results Exceed Expectations: Xenon announced that its azetukalner showed a median percent change of 53.2% in monthly focal onset seizure frequency at the 25 mg dose, significantly outperforming the placebo's 10.4%, which not only validates the drug's efficacy but also lays a solid foundation for future FDA submissions.
- New Drug Application Plans: The company plans to submit a new drug application for azetukalner to the U.S. FDA in Q3 2026, with CEO Ian Mortimer stating that the trial results “exceeded expectations,” potentially reshaping the epilepsy treatment landscape to meet the needs of 50% of patients seeking better control.
- Positive Market Reaction: Following the trial data announcement, Xenon's stock surged 50%, with Jefferies and RBC Capital raising their price targets to $100 and $80 respectively, reflecting strong market confidence in azetukalner and its significant sales potential in the future.
- Competitor Dynamics: Despite Biohaven's opakalim having safety disadvantages, Raymond James maintains a ‘Strong Buy’ rating, anticipating pivotal trial results in H2 2026 that will further clarify its market positioning.
See More
Biohaven Shares Fluctuate Following Positive Study Data
- Positive Clinical Data: Xenon Pharmaceuticals' X-TOLE2 study demonstrated a median percentage change of -42.7% in monthly focal onset seizure frequency for azetukalner at the 25 mg dose, providing short-term support for Biohaven's stock, despite its own BHV-7000 failing to meet primary endpoints in a Phase 2 trial for depression.
- Stock Performance Analysis: Biohaven shares peaked at $12.52 during premarket trading on Monday but fell back to $9.93, which is 12.5% below its 20-day simple moving average, indicating a bearish trend in the short term, with a 64.95% decline over the past year.
- Technical Indicator Insights: The current Relative Strength Index (RSI) stands at 36.10, indicating neutral territory, while the MACD value of -0.3294 is below its signal line of -0.1633, suggesting bearish pressure on the stock, with key resistance at $10.50 and support at $9.50.
- Analyst Ratings and Targets: While Biohaven's stock carries a Buy rating with an average price target of $30.36, recent actions show HC Wainwright & Co. lowering its target to $10.00, while RBC Capital raised its target to $23.00, reflecting differing analyst perspectives on the stock's outlook.
See More
Biohaven Reports Q4 Non-GAAP EPS Beat Expectations
- Earnings Performance: Biohaven reported a Q4 non-GAAP EPS of -$0.90, beating market expectations by $0.06, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Cash Reserves: As of December 31, 2025, Biohaven's cash, cash equivalents, marketable securities, and restricted cash totaled approximately $322 million, providing ample funding for future R&D and operations, thereby reducing the risk of a cash flow crisis in the short term.
- Stock Issuance Plan: Biohaven plans to sell 12.5 million shares to Janus Henderson for gross proceeds of $125 million, which will help strengthen the company's capital structure but may also lead to dilution risks for shareholders, necessitating careful assessment of its long-term impact.
- Market Reaction: Biohaven's presentation at the J.P. Morgan Healthcare Conference garnered investor interest, and despite challenges related to cash flow and dilution risks, the market maintains a cautiously optimistic outlook on its future growth opportunities, reflecting investor expectations for potential upside.
See More
Wall Street Analysts Upgrade Ratings and Price Targets for Multiple Companies
- Watts Water Upgrade: Keybanc analyst Jeffrey Hammond upgraded Watts Water Technologies Inc (NYSE:WTS) from Sector Weight to Overweight with a price target of $340, reflecting confidence in its growth potential, closing at $289.31 on Tuesday.
- Biohaven Price Target Raised: RBC Capital analyst Leonid Timashev upgraded Biohaven Ltd (NYSE:BHVN) from Sector Perform to Outperform, raising the price target from $9 to $22, indicating optimism about its product prospects, with shares closing at $12.68 on Tuesday.
- Ulta Beauty Rating Upgrade: Raymond James analyst Olivia Tong upgraded Ulta Beauty Inc (NASDAQ:ULTA) from Outperform to Strong Buy, increasing the price target from $605 to $790, showcasing strong confidence in its market performance, with shares closing at $675.62 on Tuesday.
- Albemarle Price Target Increase: Truist Securities analyst Peter Osterland upgraded Albemarle Corp (NYSE:ALB) from Hold to Buy, boosting the price target from $125 to $205, signaling positive expectations for its future performance, with shares closing at $172.54 on Tuesday.
See More
RBC Upgrades Biohaven to Outperform on Positive Drug Data, $22 Price Target Implies 74% Upside
- Rating Upgrade: RBC Capital Markets upgraded Biohaven from sector perform to outperform, with analyst Timashev noting that new data has reduced uncertainty around the company's epilepsy drug, setting a price target of $22, implying a 74% upside.
- Data Support: Recent January data indicates that Biohaven's Kv7 drug shows activity in the central nervous system, alleviating investors' worst-case concerns ahead of upcoming late-stage trials, thus boosting market confidence.
- Market Potential: Timashev believes the Kv7 modulator may demonstrate a better safety profile than competitors and has the potential to be a fast follower in a market that can support multiple branded drugs, enhancing Biohaven's competitive edge.
- Financial Outlook: While Biohaven still carries a relatively high risk profile, the analyst highlights that the improved financial position and discount relative to the platform's opportunity create an attractive setup for catalysts in 2H26, with successful clinical trials potentially pushing the stock price to $30, indicating nearly 137% upside.
See More
Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data
- Stock Surge: Biohaven's shares rose 3.42% to $12.10 in after-hours trading on Wednesday, reflecting positive market sentiment towards its clinical data despite a 67.11% decline over the past year.
- SEC Filing Disclosure: The company filed an investor presentation with the SEC on Monday, showcasing portfolio progress at the 44th Annual J.P. Morgan Healthcare Conference, indicating compliance with transparency and fair disclosure regulations.
- Clinical Data Highlights: BHV-1400 achieved over 60% mean Gd-IgA1 reductions in Phase 1 studies for IgA nephropathy, with two patients showing clinical improvements, underscoring the drug's potential in treating immunological diseases.
- Future Catalysts: Biohaven anticipates pivotal trial results in 2026 for multiple drugs, including those targeting obesity and Graves' disease, demonstrating the company's ongoing commitment to R&D and future growth potential.
See More
